Literature DB >> 16793528

Designing better drugs: predicting cytochrome P450 metabolism.

Marcel J de Groot1.   

Abstract

Many 3D ligand-based and structure-based computational approaches have been used to predict, and thus help explain, the metabolism catalyzed by the enzymes of the cytochrome P450 superfamily (P450s). P450s are responsible for >90% of the metabolism of all drugs, so the computational prediction of metabolism can help to design out drug-drug interactions in the early phases of the drug discovery process. Computational methodologies have focused on a few P450s that are directly involved in drug metabolism. The recently derived crystal structures for human P450s enable better 3D modelling of these important metabolizing enzymes. Models derived for P450s have evolved from simple comparisons of known substrates to more-elaborate experiments that require considerable computer power involving 3D overlaps and docking experiments. These models help to explain and, more importantly, predict the involvement of P450s in the metabolism of specific compounds and guide the drug-design process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793528     DOI: 10.1016/j.drudis.2006.05.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  23 in total

1.  Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation.

Authors:  Rongwei Shi; Yin Wang; Xiaolei Zhu; Xiaohua Lu
Journal:  J Mol Model       Date:  2011-11-12       Impact factor: 1.810

2.  Evaluation of descriptors and classification schemes to predict cytochrome substrates in terms of chemical information.

Authors:  John H Block; Douglas R Henry
Journal:  J Comput Aided Mol Des       Date:  2008-01-23       Impact factor: 3.686

Review 3.  Substrate binding to cytochromes P450.

Authors:  Emre M Isin; F Peter Guengerich
Journal:  Anal Bioanal Chem       Date:  2008-07-13       Impact factor: 4.142

Review 4.  Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.

Authors:  Eric F Johnson; J Patrick Connick; James R Reed; Wayne L Backes; Manoj C Desai; Lianhong Xu; D Fernando Estrada; Jennifer S Laurence; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2013-10-15       Impact factor: 3.922

5.  Comparative proteomics among cytochrome p450 family 1 for differential substrate specificity.

Authors:  Siddharth S Kesharwani; Prajwal P Nandekar; Preeti Pragyan; Abhay T Sangamwar
Journal:  Protein J       Date:  2014-12       Impact factor: 2.371

Review 6.  Structural diversity of eukaryotic membrane cytochrome p450s.

Authors:  Eric F Johnson; C David Stout
Journal:  J Biol Chem       Date:  2013-04-30       Impact factor: 5.157

7.  Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions.

Authors:  Hao Sun; Chad Moore; Patrick M Dansette; Santosh Kumar; James R Halpert; Garold S Yost
Journal:  Drug Metab Dispos       Date:  2008-12-12       Impact factor: 3.922

Review 8.  The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.

Authors:  Peter Spanogiannopoulos; Elizabeth N Bess; Rachel N Carmody; Peter J Turnbaugh
Journal:  Nat Rev Microbiol       Date:  2016-03-14       Impact factor: 60.633

9.  Predicting CYP2C19 catalytic parameters for enantioselective oxidations using artificial neural networks and a chirality code.

Authors:  Jessica H Hartman; Steven D Cothren; Sun-Ha Park; Chul-Ho Yun; Jerry A Darsey; Grover P Miller
Journal:  Bioorg Med Chem       Date:  2013-04-22       Impact factor: 3.641

Review 10.  Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping.

Authors:  Ioannis S Vizirianakis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.